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Idiopathic membranous nephropathy (IMN) has a strong
association with the major histocompatibility complex HLA
B8DR3(17)DQ2 haplotype. The tumor necrosis factor (TNF)A
gene is located within the major histocompatibility complex
region on chromosome 6. We have studied the influence of
two functional polymorphisms; the 308 (promoter region)
and the TNFd microsatellites on initiation and/or progression
of IMN. This was a case–control study comparing data from
100 Caucasians patients (67 male subjects; 67%) with IMN to
232 Caucasians local controls (171 male subjects; 74%). We
have analyzed genotypes and alleles distributions and the
role of these polymorphisms in disease progression towards
end-stage renal failure or patient death. For 308 TNFA
polymorphism, distribution of genotypes was significantly
different between IMN and controls (v2¼ 16.25; P¼ 0.0003):
the A2 allele frequency was 28.0% in IMN vs 15.3% in
controls (v2¼ 14.57; P¼ 0.0001). For TNFd polymorphism,
alleles distribution (from d1 to d7) was also significantly
different between IMN and controls (v2¼ 56.74; Po0.0001)
with both diminished d3 allele frequency (v2¼ 27.30;
Po0.0001; Pc¼ 0.001) and increased d2 allele frequency
(v2¼ 29.95; Po0.0001; Pc¼ 0.001) in IMN. We could not
isolate any significant and independent influence of these
different genotypes on IMN disease progression. The TNFA2
and TNFd2 alleles were strongly associated with occurrence/
initiation of IMN and should be considered as susceptibility
genes for this disease.
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Membranous nephropathy (MN) is a rare disease and is
classically the prototype of immune complexes glomerulone-
phritis. The rat model of MN is the heymann glomerulone-
phritis (active and passive forms).1 Autoantibodies directed
against glycoprotein 330 (gp330) or megalin-bound com-
plexes were found in rats but not in humans.2
Hypothesis on antibodies deposition mechanisms are: (i)
deposition of circulating immune complexes, (ii) deposition
of antibodies on kidney constitutive antigen and, (iii)
deposition of antibodies on kidney cell-fixed antigen so
called planted antigens.3
The pivotal cell of the disease is the glomerular visceral
epithelial cell also called podocyte. The complement
membrane attack complex, C5b-9, plays a crucial role and
acts as a sublytic pattern on podocyte with phospholipase A2
activation and DNA damage rather than lytic injury.4,5,6 In
humans, a large variety of antigens have been identified and
deposited in the kidney, more precisely on the epithelial side
of glomerular basement membrane together with immuno-
globulins (as antibodies) and complement. These antigenic
epitopes may belong to infectious agent (such as hepatitis B
virus as an example), tumors or toxic agent (such as gold or
mercury). When a specific cause is found, the disease is called
secondary MN. By contrast, in the majority of human cases,
no cause could be identified and the disease is then called
idiopathic membranous nephropathy (IMN).
Tumor necrosis factor (TNF)a is a proinflammatory,
antitumoral, and activator of immune system cytokine.7,8
The TNFA gene lies within the major histocompatibility
complex genes on short arm of chromosome 6, in the human
leukocyte antigen (HLA) class III region, in a position
defined as 250 kb centromeric to HLA-B locus and about
850 kb telomeric to HLA-DR locus.9 Different polymorph-
isms have been described for TNFa cytokine gene(s), but we
focused on two functional variants associated with increased
TNFa serum level:
K The TNFA single-nucleotide polymorphism at
position 308 in the promoter region9 with a
guanine (TNFA1 allele) to adenine (TNFA2 allele)
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mutation (G/A). This TNFA2 allele is associated
with the HLA A1/B8/DR17/DQ2 extended haplo-
type, which was also reported as a marker of
autoimmunity.9
K The TNFd microsatellite polymorphism10 located
8 kb downstream to TNFA gene. It consist of various
dinucleotide repeats (GA) termed TNFd1–d7 with a
greater TNFa cytokine production associated with
TNFd3 allele.
IMN was also found to be an HLA-associated disease and
more precisely with B8 and/or DR17(3) in the caucasian
population.11–13 The relative risk to develop a MN with a
gold treatment was increased 32-fold if you carry the DR3
antigen.11 Moreover, B8/DR3 haplotype was associated with
high production of TNFa in vivo and in vitro.14
A direct role of TNFa in IMN is possible: Wu et al.15 found
an excessive expression of the TNFA gene in the kidneys of
patients with membranous glomerulonephritis. TNFa was
expressed by glomerular visceral epithelial cells in human
MN.16 Urinary excretion of TNFa was increased in IMN vs
controls; this was correlated with overexpression of leukocyte
function antigen 1 in kidney interstitial tissue.17 Moreover,
TNFa was able to induce dyscohesion at the slit membrane
level with disassembly of actin filaments;18 indeed, Yuan
et al.19 found that nephrin dissociates from actin with a
reduced expression in early experimental MN.
Taken together, these data led us to investigate whether
TNFa gene polymorphisms could play a significant role in
patients with IMN.
The aim of this study was to detect any influence of these
two TNFa polymorphisms: – on the onset/occurrence of the
disease by comparing alleles and genotypes distributions
between IMN and appropriate controls and – on the
progression of the disease by comparing clinical/pathological
parameters according to the different genotypes either single
or in combination.
RESULTS
Influence of TNFa polymorphisms on occurrence/onset of
IMN disease
TNF genotypes (308 position) distribution and allelic
frequencies. The results are given in Table 1. The genotypes
distribution between IMN patients and controls was
significantly different (w2¼ 16.25; P¼ 0.0003). More pre-
cisely, the A2 allele was significantly more frequent in IMN
patients vs controls (28 vs 15.3%; w2¼ 14.57; P¼ 0.0001).
Patients carrying the A2 allele (A2/A2þA1/A2) were 51 vs
28.0% in controls (w2¼ 16.24; Po0.0001).
TNFd microsatellite polymorphism. The results are given in
Table 2. The six alleles distribution was significantly different in
IMN vs controls (w2¼ 56.74; Po0.0001, Pc¼ 0.001). Sub-
analysis demonstrated in IMN patients a significant decreased
frequency of the d3 allele vs controls (w2¼ 27.30; Po0.0001,
Pc¼ 0.001) and a contrario a significant increase of d2 allele as
compared to controls (w2¼ 29.95; Po0.0001, Pc¼ 0.001).
Combined TNFA and TNFd genotypes and alleles. The
results are given in Table 3. The increased frequencies of A2
and/or d2 alleles were pooled (52.0% in IMN patients vs
30.2% in controls, w2¼ 14.32; P¼ 0.0002). Note that there
were only four A2/d2 individuals in the control group vs 24
in the IMN group.
Validity of the data. The number of observed genotypes
was not significantly different by the w2 test from the
theoretical numbers calculated from the Hardy–Weinberg
equilibrium using the allelic frequencies (see Appendix).
Table 1 | TNFA (polymorphism at position –308) genotypes
and alleles frequencies in IMN vs controls
Controls IMN v2 P-value
n (%) n (%)
Genotypes
A1/A1 167 (72.0) 49 (49.0)
A1/A2 59 (25.4) 46 (46.0) 16.25 0.0003
A2/A2 6 (2.6) 5 (5.0)
Total 232 (100) 100 (100)
Alleles
A1 393 (84.7) 144 (72.0)
A2 71 (15.3) 56 (28.0) 14.57 0.0001
Total 464 (100) 200 (100)
Restricted genotypes
With A2 allele 65 (28.0) 51 (51.0)
A1A1 167 (72.0) 49 (49.0) 16.24 o0.0001
Total 232 (100) 100 (100)
IMN, idiopathic membranous nephropathy; TNF, tumor necrosis factor.
Table 2 | TNFd (microsatellite polymorphism) alleles
frequencies in IMN vs controls
Alleles Controls IMN v2 P-value
n (%) n (%)
(a) TNFd alleles frequencies
d1 48 (10.3) 18 (9.0)
d2 10 (2.2) 25 (12.5)
d3 234 (50.4) 57 (28.5)
d4 118 (25.4) 65 (32.5) 56.74a o0.0001a
d5 51 (11.0) 27 (13.5)
d7 3 (0.7) 8 (4.0)
Total 464 (100) 200 (100)
(b) TNFd alleles frequencies subanalysis
d2 10 (2.2) 25 (12.5) 29.95b o0.0001b
Non-d2 454 (97.8) 175 (87.5) Pc=0.001c
Total 464 (100) 200 (100)
(c) TNFd alleles frequencies subanalysis
d3 234 (50.4) 57 (28.5) 27.30b o0.0001b
Non-d3 230 (49.6) 143 (71.5) Pc=0.001c
Total 464 (100) 200 (100)
IMN, idiopathic membranous nephropathy; TNF, tumor necrosis factor.
aValue comparing all the distribution (at the same time).
bValue comparing both alleles.
cPc=P 6, corrected for the number of alleles tested, that is, 6(d1–d7, with d6
absent).
432 Kidney International (2007) 71, 431–437
o r i g i n a l a r t i c l e D Thibaudin et al.: Idiopathic membranous nephropathy
TNFA, TNFd, and combined TNFA/TNFd genotypes and alleles
according to the presence or absence of B8/DR3/DQ2 haplo-
type. The results are given in Table 4. We found the B8/
DR3/DQ2 haplotype in 54% of IMN patients. All A2A2
patients were B8/DR3/DQ2. There was a strong association in
patients between A2 allele and extended haplotype
(Po0.001) on one hand and between d2 allele and extended
haplotype (Po0.003). We observed the same finding for
combined genotype A2 a/o d2 and extended haplotype (75.9
vs 23.9%, Po0.0001). In addition, d2 and d3 alleles were
mutually exclusives. It is important to note that in the IMN
subgroup without HLA-B8/DR3/DQ2 haplotype, the geno-
types and alleles concerning the different TNF polymorph-
isms were not different from controls.
The HLA-B8 and HLA-DR3 antigens distribution in IMN
patients compared with controls confirmed the already well-
known and significant association between HLA-B8 and/or
HLA-DR17(3) in IMN (data not shown).
Influence of TNFa polymorphisms on the progression of IMN
disease
TNFA genotypes. We compared clinical and pathological
data between patients bearing the A1A1 genotype vs those
with A1A2/A2A2 genotypes, that is, with the A2 allele. There
was no significant difference both at diagnosis and at last
follow-up.
TNFd genotypes. We compared patients with d2/non-d2
vs non-d2/non-d2 genotypes. There were no patients
homozygous for d2. Again, we could not find any difference.
Combined TNFA and TNFd genotypes. We compared A2 a/o
d2 with non-A2/non-d2 patients. Once again, we found no
difference. All these TNFa genotypes played no significant
role if any in the progression of the disease.
According to the presence or absence of B8/DR3/DQ2
haplotype. Fifty-four patients (54.0%) had the B8/DR3/
DQ2 haplotype. We found a significant difference for follow-
up time from onset: 104.8 (788.4) for patients with B8/DR3/
DQ2 haplotype vs 70.4 (762.4) months (P¼ 0.03) but these
patients were younger at the onset of their disease (46.3 vs
49.6 years, NS). But again, this haplotype had no role in the
progression of the disease.
Survival curves without ESRF/death (primary end point). Results
are given in Figures 1–3: All these TNFa polymorphisms have no
influence on survival without renal/patient death. We have used
the Cox monovariate analysis in the search of significant factors
influencing survival without renal/patient death (Table 5). We
have found only two factors: gender and amount of proteinuria.
Multivariate Cox regression demonstrated that only gender was
an independent risk factor for progression to renal/patient
death: male gender was associated with a relative risk of about 11
compared to 1 for female.
DISCUSSION
In this report, TNFA2 allele (308 promoter) and TNFd2
allele (microsatellite TNFd) were strongly associated with the
Table 3 | Combined TNFA and TNFd genotypes according to
the presence or absence of A2 and/or d2 alleles
Combined genotypes Controls IMN v2 P-value
n (%) n (%)
A2 a/o d2 70 (30.2) 52 (52.0) 14.32 0.0002
Non-A2/non-d2 162 (69.8) 48 (48.0)
Total 232 (100) 100 (100)
IMN, idiopathic membranous nephropathy; TNF, tumor necrosis factor.
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Figure 1 | Survival without ESRF (dialysis) or death and according
to the TNFA genotypes.
Table 4 | TNFA (polymorphism at position –308) genotypes
and alleles, TNFd (microsatellite polymorphism) genotypes
and combined TNFA/TNFd genotypes distribution according
to the presence or absence of the B8/DR3/DQ2 haplotype
B8/DR3/DQ2 Non-B8/DR3/DQ2 v2 P-value
n (%) n (%)
Genotypes
A1/A1 14 (25.9) 35 (76.1)
A1/A2 35 (64.8) 11 (23.9) 26.05a o0.0001a
A2/A2 5 (9.3) 0 (0.0)
Total 54 (100) 46 (100)
Alleles
A1 63 (58.3) 81 (88.0) 21.75a o0.0001a
A2 45 (41.7) 11 (12.0)
Total 108 (100) 92 (100)
Genotypes
d2/non-d2 20 (37.0) 5 (10.9) 9.07a 0.003a
Non-d2/non-d2 34 (63.0) 41 (89.1)
Total 54 (100) 46 (100)
Combined genotypes
A2 a/o d2 41 (75.9) 11 (23.9) 26.92a o0.0001a
Non-A2/non-d2 13 (24.1) 35 (76.1)
Total 54 (100) 46 (100)
TNF, tumor necrosis factor.
aValue comparing all genotypes/alleles.
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onset/occurrence of IMN; they are susceptibility genes for
IMN and a contrario, d3 allele could be considered as a
protective gene. D2 and d3 alleles are mutually exclusive in
our patients. Bantis et al.20 had performed a similar study but
limited to TNFA polymorphism in 53 IMN patients and 100
controls. A2A2 was found in 9.4% in IMN patients and 2.0%
in controls, and A2 allele in 34% in IMN patients and 15% in
controls. Our present study found similar results (A2 allele:
15.3% in controls vs 28.0% in IMN). This finding is different
from a population of immunoglobulin A nephropathy
patients where d3 allele is the most frequent.21 In addition,
d2 and A2 alleles were strongly associated with the highly
conserved HLA-B8/DR3/DQ2 extended haplotype. These
different markers are in strong disequilibrium. This HLA
haplotype is classically associated with IMN.11–13
By contrast, we found that A2 and/or d2 alleles played no
significant role if any in the progression of IMN disease. We
have observed a global proportion of end-stage renal failure
(ESRF)/dialysis death around 20%; a contrario the propor-
tion of patients without is about 80%. The small number of
patients could permit only to detect a large difference of
outcome (very unlikely): proportion reduces to 0.55 with the
power of 80% (54 2 patients needed from the Table).22 So
clearly we were under powered to detect a smaller difference.
Our negative findings concerning the association between the
different alleles and IMN outcome could be due to this
underpower (number of patients too limited).
Actually it seems important to study polymorphisms that
have been shown to have a direct effect on gene function.23
This is the case for the two studied TNFA polymorphisms: in
hematopoietic stem cell transplantation, the presence of an
adenine at position 308 (TNFA2 allele) has been reported
to result in a twofold greater level of transcription than the
common A1 allele;24 – in Crohn’s patients with fistulizing
disease, those carrying A1A2 as compared to A1A1 patients
had a significant increase of serum level of TNFa (58þ /79
vs 8þ /19 pg/ml, Po0.001);25 – the microsatellite allele
TNFd3 was significantly associated with the capacity of
leukocytes to produce TNFa in vitro in heart transplant
recipients;26 – in addition, an overproduction of serum TNFa
was demonstrated in individuals bearing the B8/DR3/DQ2
haplotype.14 So, we could speculate that this overproduction
of serum TNFa observed in individuals with B8/DR3/DQ2
haplotype could be linked to the association of B8/DR3/DQ2
haplotype with A2 a/o d2 alleles.
One of the aims of genetic studies is to provide knowledge
about the prognosis of a given disease. IMN shows large
inter-individual variations in the rate of progression to
chronic renal failure (CRF) and ESRF. A significant fraction
of IMN patients has a spontaneous and complete recovery of
her disease (about 25–33% in the literature and 25.0% in our
study). A similar fraction progresses to CRF and then to
ESRF (21.0% in our study). It’s difficult but very important
to early determine patients at risk for progression. Indeed,
aggressive therapy with steroids and immunosuppressive
drugs such as Ponticelli’s protocol27 or cyclosporine A28 must
Table 5 | Influence of different covariates on survival without
ESRF/death by Cox univariate analysis
Covariate b/s.e. v2 P-value RR (95% CI)
A2 allele 1.58 2.50 NS
d2 allele 0.34 0.12 NS
Combined A2 a/o d2 1.20 1.43 NS
Gender: male 2.38 5.67 0.02 11.49 (1.54-85.66)
Proteinuria/RB1 (g/d) 2.83 8.02 0.05 1.07 (1.02-1.12)
Hypertension/RB1 :absence 0.92 0.85 NS
IMN stages/RB1:1/2 8.97 8.05 NS
CRF/RB1:absence 1.52 2.32 NS
Age at RB1 (y) 1.10 1.21 NS
CI, confidence interval; CRF, chronic renal failure; d, day; ESRF, end-stage renal
failure; IMN, idiopathic membranous nephropathy; RB1, renal biopsy 1; RR, relative
risk; s.e., standard error; y, year.
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A2 and/or d2 
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Figure 3 | Survival without ESRF (dialysis) or death and according
to the combined TNFA/TNFd genotype.
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Figure 2 | Survival without ESRF (dialysis) or death and according
to the TNFd alleles.
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be selected for patients at high risk of progression and not for
the others because of side effects. In the literature, numerous
factors predicting poor prognosis have been isolated: male
gender, white ‘race’, advanced age at onset, tubulointerstitial
changes or focal sclerosis, pathological stages III/IV, ne-
phrotic syndrome, amount of immunoglobulin G urinary
excretion or b2-microglobulin urinary excretion, low serum
albumin, high serum cholesterol, amount of urinary excre-
tion of complement activation products, impaired renal
function at diagnosis, and hypertension.29,30 Among these
factors, nephrotic syndrome and pathological stages III/IV
appear to be the best predictors.26 Hence, patients with heavy
proteinuria for more than 6–12 months have a 66%
probability of developing renal insufficiency.31 In another
study, the HLA-B8/DR3/DQ2 haplotype was also linked to
occurrence of IMN but not with progression.30 In our study,
the most important predictor for ESRF/death was male
gender but not nephrotic syndrome or pathological stages
III/IV or TNFa polymorphisms.
The role of TNFa in the pathogenesis of IMN is supported
by evidence of high urinary levels of this cytokine in patients
with the disease.17,32,33 TNFa is found in the cytoplasm of
glomerular epithelial cells in children34 and is expressed in
these cells in human MN.16 Several studies have demon-
strated a TNFa production by monocytes or peripheral blood
mononuclear cells in MN35 or in nephrotic syndrome.33,36
Moreover serum TNFa levels were increased in patients with
MN33,37 and other renal diseases (including MN) with the
nephrotic syndrome.36 These findings support the possibility
that TNFa may play a pathogenic role in the induction or
maintenance of glomerular barrier dysfunction in humans.
Three therapeutic agents, capable of blocking TNFa
activity, have recently drawn attention to their potential use
in the IMN treatment: pentoxifylline (an old drug),
infliximab (a monoclonal antibody), and etanercept (a fusion
protein). Pentoxifylline is a phosphodiesterase inhibitor that
is best known for its use in symptomatic peripheral vascular
disease. It has strong anti-inflammatory properties such as
reducing the production of TNFa, as well as other cytokines
in normal and diseases states.32 Ducloux et al.38 demon-
strated in 10 patients with IMN a high rate of remission (nine
for 10 patients). Moreover, the mean plasma TNFa level
decreased from 12 to 0.5 pg/ml, and the mean urine TNFa
from 2.5 to 0.3 pg/ml.38 Etanercept and infliximab have a
strong theoretical basis for potential efficacy but so far no
data has been yet reported.
MATERIALS AND METHODS
Subjects
This is a case–control study involving a group of patients with the
disease and an appropriate control group. All individuals gave
informed consent to this genetic study.
Patients. We have studied 100 consecutive Caucasian patients
(67 male subjects, 67%) with IMN, diagnosed at our institution
between 1975 and 2002. Patients with any evidence of secondary
causes such as systemic lupus or specific other causes were excluded.
Renal biopsy was performed in all patients usually few weeks after
onset of nephrotic syndrome with edema and at most 3 months. For
this reason, onset of the disease was chosen as the date of first renal
biopsy (RB1). At time of the diagnosis (RB1), the age of these
patients was 48.7(715.2) for male subjects and 46.1(719.2) years
for female subjects; body mass index was 24.95(74.29), fifty one
(51%) were already hypertensive, 14 with CRF but none in ESRF
requiring dialysis. Overall, we have observed only three deaths in
this IMN cohort. This cohort is obviously not a natural history
cohort over 25 years. All these patients were treated according to
their need. All hypertensive recipients receiving optimal antihyper-
tensive therapy. In addition for their heavy proteinuria they have
received the following treatments (plus prevention of thrombosis):
82 patients received platelet antiaggregants a/o anticoagulants, 66
patients ACEI a/o ARB, 43 patients steroids (alone or in the
Ponticelli’s protocol), 35 patients non-steroidal anti-inflammatory
drugs, 25 patients Ponticelli’s protocol, 10 cyclosporine A, seven
patients pentoxyfilline, six patients cyclophosphamide, and five
patients IV immunoglobulin. Some patient had received more than
one treatment during the course of the disease. We cannot exclude a
confounding role of these treatments. Nevertheless, we showed that
patients with a favorable outcome did not receive a heavier
treatment.
Clinical data
We collected for these patients at biopsy, at regular interval and at
last follow-up the following parameters: the amount of proteinuria
(g/24 h), plasma creatinine (mmol/l), the presence of arterial
hypertension defined as blood pressure 4140/90 mmHg on at least
two occasions and/or the regular use of antihypertensive medica-
tions, the presence of CRF, defined as calculated creatinine clearance
according to Cockcroft and Gault formula below 60 ml/min for at
least 3 months39 and the presence of ESRF, defined as the need for
renal replacement therapy (Cockcroft was always below 15 ml/min,
but usually between 8 and 10).
Pathological data at RB1
The scoring was performed by our renal pathologist as a routine
procedure without knowledge of the clinical data. We use
classification in four stages by optical microscopy: I–IV according
to the description by Ehrenreich.40
Clinical progression
The primary combined end point was occurrence of either ESRF
(renal death) or patient death. The secondary end points were
occurrence of hypertension and occurrence of CRF, as already
defined.
Controls. Our control group was matched for gender according
to the male predominance of IMN and consisted of 232 local
Caucasian healthy adults (171 male subjects, 74%) and will
represent the local general population. Age at sampling was different
in controls (41.6 years). vs IMN patients (47.8 years) (w2¼ 3.41,
Po0.001). In controls, weight was 69.96 kg, height 1.72 m and body
mass index 23.58. Controls are 77 local healthy volunteers and 155
blood donors, all living in the Saint-Etienne area.
Methods
Genotyping of 308 TNFa polymorphism. Genomic DNA was
obtained from peripheral blood mononuclear cells with a classical
phenol–chloroform extraction method. A polymerase chain reaction
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coupled with restriction fragment length polymorphism (PCR) was
used for amplification and accurate genotyping. The sequence of the
primers was chosen for the amplification of a 289 bp DNA fragment,
including the polymorphic nucleotide ((G-308A), were the follow-
ing: 50-AGGCAATAGGTTTTGAGGGCCAT-30 (sense) and 50-
CAGCGGAAAACTTCCTTGGT-30 (antisense). The PCR technique
was performed on 250 ng of extracted DNA: DNA amplification
with 1.25 U of Taq DNA polymerase (Gibco-BRL-Invitrogen, Cergy
Pontoise, France) in 20 mM Tris-HCl containing 50 mM KCl, 1.5 mM
MgCl2, 200 mmol/l dNTP, and 0.5 mM of each primer. After an initial
denaturing time of 5 min at 901C, PCR reactions were run for 35
cycles including 30 s at 941C, 30 s at 601C, and 1 min at 721C.
The PCR product was digested by 5 U of the enzyme NcoI at
371C for 3 h and then subjected to electrophoresis in 2% agarose gel
(Metaphor agarose; FMC-BioProducts, Rocklands, Maine, USA)
stained with ethidium bromide. The TNFA-1 allele gave two bands
at 244 and 20 bp respectively and the TNFA-2 allele gave only one
band at 264 bp. As the very light band of 20 bp migrates too fast to
be detected on the gel, the TNFA-1 allele was in practice
characterized by only one band at 244 bp. Finally, the genotypes
were defined as 1/1 (homozygous) in case of a unique band at
244 bp, as 2/2 (homozygous) in case of a unique band at 264 bp and
as 1/2 (heterozygous) in case of two bands –one at 244 bp and one at
264 bp.
Genotyping of TNFd microsatellite polymorphism. The poly-
morphism is based on the number of GA repeats. It was detected by
PCR followed by polyacrylamide gel electrophoresis to separate the
different DNA fragments of 126, 128, 130, 132, 134, and 138 bp. The
primers used were: TNFd12 sense, 50-CATAGTGGGACTCTGTCTC
CAAAG-30; TNFd11 antisense, 50-AGATCCTTCCCTGTGAGTT
CTGCT-30. For the PCR, we used 250 ng of extracted DNA,
amplified with 1.25 U of Taq polymerase (Gibco BRL) in 20 mM
Tris-HCl containing 50 mM KCl, 1.5 mM MgCl2, 200mm of each
dNTP, and 0.4 mM of each primer. After an initial denaturation at
941C for 2 min, PCR reactions were run for 30 cycles including 15 s
at 941C, 15 s at 551C, 30 s at 721C and one cycle with 2 min at 721C
and 1 min at 301C.
The PCR products obtained were submitted to polyacrylamide
gel electrophoresis (12% acrylamide/bisacrylamide 19:1) and the
bands obtained permitted the characterization of the different alleles
d1, d2, d3, d4, d5, and d7; d6 was never found.
For both polymorphisms, we have verified that the genotype
distributions observed were in accordance with the Hardy–Weinberg
equilibrium.
Major histocompatibility complex class I and class II anti-
gens. These determinations were carried out on a routine basis by
the HLA typing laboratory of the Etablissement Franc¸ais du Sang in
Saint-Etienne (Dr JC Le Petit), involved in our transplant program.
All 100 patients were HLA types using molecular techniques for class
II antigens (except for few patients) and serological techniques for
class I antigens. The HLA-B8 and HLA-DR17 antigens distributions
in IMN patients were compared to the local controls established by
the HLA typing laboratory.
Statistical analysis
Comparison between patients and controls. The different
allelic frequencies and genotype distributions were compared using
the w2 contingency table for qualitative variables. When applicable,
the P-value obtained was corrected (Pc) for the number of alleles
tested (six for TNFd). With the results of A1 allele distribution in
controls approximately 0.85 and in patients 0.70 in a total group of
664 alleles (332 individuals but imbalance of numbers between
controls and IMN) the power is over 95% with risk a¼ 0.05 as
shown in specialized table of Arkim and Wachted.22
Clinicopathological parameters among patients with different
genotypes. The qualitative variables, such as pathological stages
(Iþ II vs IIIþ IV), hypertension, CRF, and ESRF, were compared
using the w2 contingency table. The quantitative variables, such as
proteinuria, follow-up duration and serum creatinine, were
compared using either the unpaired t-test or non-parametric test
(Mann–Whitney U-test) when applicable. Survival curves were
analyzed according to the Kaplan–Meier method: the events
were ESRF/death or CRF; time zero was the date of RB1 (onset of
the disease) and the final date was either the event date or the last
follow-up date (censored patients). The curves obtained were
compared according to the log-rank test. In case of significant
results, additional multivariate Cox regression analysis was
performed with the following covariates at RB1: age, gender,
amount of proteinuria, and class of RB1 stages.
REFERENCES
1. Heymann W, Hackel DB, Harwood S et al. Production of nephrotic
syndrome in rats by Freund’s adjuvants and rat kidney suspensions.
Proc Exp Biol Med 1959; 100: 660–664.
2. kerjaschki D. Pathogenic concepts of membranous glomerulopathy
(MGN). J Nephrol 2000; 13(Suppl3): S96–S100.
3. Shankland SJ. New insights into pathogenesis of membranous
nephropathy, editorial. Kidney Int 2000; 57: 1204–1205.
4. Montinaro V, Lopez A, Monno R et al. Renal C3 synthesis in idiopathic
membranous nephropathy: correlation to urinary C5b-9 excretion. Kidney
Int 2000; 57: 137–146.
5. Cybulsky AV, Takano T, Papillon J et al. Complement-induced
phospholipase A2 activation in experimental membranous nephropathy.
Kidney Int 2000; 57: 1052–1062.
6. Pippin JW, Durvasula R, Petermann A et al. DNA damage is a novel
response to sublytic complement C5b-9-induced injury in podocytes.
J Clin Invest 2003; 111: 877–885.
7. Rink L, Kircner H. Recent progress in tumor necrosis factor-alpha field.
Int Arch Allergy Immunol 1996; 111: 199–209.
8. Ruddle NH. Tumor necrosis factor (TNFa) and lymphotoxin (TNFb).
Curr opin Immunol 1992; 4: 327–332.
9. Wilson AG, de Vries N, Pociot F et al. An allelic polymorphism within the
human tumor necrosis factor alpha promoter region is strongly
associated with HLA, A1, B8 and DR3 alleles. J Exp Med 1993; 177:
557–560.
10. Udalova IA, Nedospasov SA, Webb GC et al. Highly informative typing of
human TNF locus using six adjacent polymorphic markers. Genomics
1993; 16: 180–186.
11. Glotz D, Bariety J, Druet PH. Glome´rulone´phrites extramembraneuses. Rev
Prat 1991; 41: 2424–2429.
12. Berthoux FC, Berthoux P, Hassan AA et al. Immunoge´ne´tique des
glome´rulone´phrites extramembraneuses primitives. Presse Med 1990; 19:
990–993.
13. Berthoux FC, Laurent B, Le Petit JC et al. Immunogenetics and
immunopathology of human primary membranous glomerulonephritis:
HLA-A B DR antigens; functional activity of splenic macrophage Fc-
receptors and peripheral blood T-lymphocyte subpopulations. Clin
Nephrol 1984; 22: 15–20.
14. Lio D, Candore G, Colombo A. A genetically determined high setting of
TNFa influences immunologic parameters of HLA-B8, DR3 positives
subjects: implications for autoimmunity. Hum Immunol 2001; 62:
705–713.
15. Wu TH, Tsai CY, Yang WC. Excessive expression of the tumor necrosis
factor-alpha gene in the kidneys of patients with membranous
glomerulonephritis. Chug Hua I Hsueh Tsa Chih 1998; 61: 524–530.
16. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is
expressed by glomerular visceral epithelial cells in human membranous
nephropathy. Am J Pathol 1995; 146: 1444–1455.
17. Honkanen E, von Willebrand E, Teppo AM et al. Adhesion molecules and
urinary tumor necrosis factor-alpha in idiopathic membranous
glomerulonephritis. Kidney Int 1998; 53: 909–917.
436 Kidney International (2007) 71, 431–437
o r i g i n a l a r t i c l e D Thibaudin et al.: Idiopathic membranous nephropathy
18. Tabibzadeh S, Kong KF, Kapur S et al. TNF-alpha induces dyscohesion of
epithelial cells – association with disassembly of actin filaments. Endocr J
1995; 3: 549–556.
19. Yuan H, Takeuchi E, Taylor GA et al. Nephrin dissociates from actin, and its
expression is reduced in early experimental membranous nephropathy.
J Am Soc Nephrol 2002; 13: 946–956.
20. Bantis C, Heering PJ, Aker S et al. Tumor necrosis factor-a gene G-308A
polymorphism is a risk factor for the development of membranous
glomerulonephritis. Am J Nephrol 2006; 26: 12–15.
21. Tuglular S, Berthoux P, Berthoux F. Polymorphisms of the tumour
necrosis factor a gene at position 308 and TNFd microsatellite in
primary IgA nephropathy. Nephrol Dial Transplant 2003; 18: 724–731.
22. Arkin CF, Wachtel MS. How many patients are necessary to assess test
performance? JAMA 1990; 263: 275–278.
23. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic
associations with complex outcomes. Lancet 2003; 361: 865–872.
24. Kroeger KM, Carville KS, Abraham LJ. The 308 tumor necrosis
factor-alpha promoter polymorphism effects transcription. Mol
Immunol 1997; 34: 391–399.
25. Gonzalez S, Rodrigo L, Martinez-Borra J et al. TNF-alpha 308A promoter
polymorphism is associated with enhanced TNF-alpha production and
inflammatory activity in Crohn’s patients with fistulizing disease. Am J
Gastroenterol 2003; 98: 1101–1106.
26. Turner DM, Grant SC, Lamb WR et al. A genetic marker of high TNF-alpha
production in heart transplant recipients. Transplantation 1995; 60:
1113–1117.
27. Ponticelli C, Zucchelli P, Imbasciati E. Controlled trial of
methylprednisolone and chlorambucil in idiopathic membranous
nephropathy. N Engl J Med 1984; 310: 946–950.
28. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with
steroid-resistant membranous nephropathy: a randomized trial. Kidney Int
2001; 59: 1484–1490.
29. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy.
Kidney Int 1999; 56: 666–673.
30. Reichert LJM, Koene RAP, Wetzels JFM. Prognostic factors in idiopathic
membranous nephropathy. Am J Kidney Dis 1998; 31: 1–11.
31. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in
idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960–966.
32. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future
intervention for treatment of membranous nephropathy. Semin Nephrol
2003; 23: 362–372.
33. Suranyi MG, Guasch A, Hall BM et al. Elevated levels of tumor necrosis
factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis 1993;
21: 251–259.
34. Nakajima M, Kawahara S, Sakagami Y et al. Immunogold labeling of
cytokines in glomeruli in children with various renal diseases. Nephron
1999; 83: 132–138.
35. Matsumoto K. Increased release of tumor necrosis factor-alpha by
monocytes from patients with glomerulonephritis. Clin Nephrol 1993; 40:
148–154.
36. Bustos C, Gonzalez E, Muley R et al. Increase of tumour necrosis factor
alpha synthesis and gene expression in peripheral blood mononuclear
cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest
1994; 24: 799–805.
37. Ihm CG, Park JK, Hong SP et al. Circulating factors in sera or peripheral
blood mononuclear cells in patients with membranous nephropathy or
diabetic nephropathy. J Korean Med Sci 1997; 12: 539–544.
38. Ducloux D, Bresson-Vautrin C, Chalopin JM. Use of pentoxifylline in
membranous nephropathy. Lancet 2001; 357: 1672–1673.
39. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for
Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J
Kidney Dis 2002; 39(Suppl1): S46–S75.
40. Ehrenreich T, Churg J. Pathology of membranous nephropathy. Pathol
Annu 1968; 3: 145–186.
APPENDIX
Example for TNFA (Table 1) in IMN patients: A1 allele
frequency¼ 0.720; A2 allele frequency¼ 0.280; A1A1 geno-
type¼ (0.720)2 100¼ 52; A2A2 genotype¼ (0.280)2
100¼ 8; A1A2 genotype¼ 2 (0.720 0.280) 100¼ 40. The
observed genotype distribution was 49, 5, and 46, respec-
tively, but not different from the theoretical distribution: 52,
8, and 40 (w2¼ 1.20, P¼NS).
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